Development of Reversible Inhibitors of Factor XIa

XIa 因子可逆抑制剂的开发

• 批准号: nhmrc : 1024982
• 负责人: A/Pr Mark Coster
• 金额: $ 29.63万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-reversible-inhibitors-factor-xia/110394
• 关键词: Development; Reversible; Inhibitors; Factor; XIa

Blood usually clots in response to injury, but unwanted clots can cause thrombosis, as well as leading to stroke and heart disease. Existing drugs to treat thrombosis suffer from drawbacks such as invasive monitoring, interaction with diet and other medicines, and bleeding complications. New drugs are clearly needed. Our expert group of researchers will discover new anti-thrombotic compounds based upon our previous identification of natural products with anticoagulant properties.

血液通常会因受伤而凝结，但不需要的凝块会导致血栓形成，还会导致中风和心脏病。现有的治疗血栓形成的药物存在诸如侵入性监测、与饮食和其他药物相互作用以及出血并发症等缺点。新的药物显然是需要的。我们的研究人员专家组将在我们之前鉴定的具有抗凝血剂特性的天然产品的基础上，发现新的抗血栓化合物。